跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 6,100 条关于
“CCM-308”
全部
6,100
临床试验
3,657
药物
1,870
机构
44
资讯
529
去年
CCM Biosciences to Present Breakthrough 4th-Generation EGFR Inhibitors for NSCLC at ASCO 2025
去年
Recursion's REC-994 Shows Promising Safety and Efficacy Signals in Phase 2 CCM Trial
9个月前
Enveda Receives FDA Clearance for First-in-Class Oral Obesity Therapy ENV-308, Doses First Patient in Phase 1 Trial
去年
Recursion's REC-994 Shows Promise in Phase II Trial for Cerebral Cavernous Malformations
2年前
Recursion's AI-Derived Drug REC-994 Shows Promise in Phase 2 Trial for Cerebral Cavernous Malformation
去年
Recursion's AI-Discovered Drug Shows Promise in Phase II Brain Disease Trial
去年
UVA Health Develops Breakthrough Non-Invasive Ultrasound Treatment for Cerebral Cavernous Malformations
2年前
AI-Driven Drug Discovery Shows Promise and Challenges in Cerebral Cavernous Malformation Trial
11个月前
STREAM Program Delivers Actionable Genomic Insights for 59% of Pediatric Cancer Patients in Asia's First Nationwide WGS Initiative
7天前
Subcutaneous Tarlatamab Matches IV Exposure With Low-Grade Toxicity in Phase 1b ES-SCLC Trial
第 1 页,共 53 页
上一页
下一页